PExA (PEXA) Q4 2024 earnings summary

Executive summary

• Net sales for 2024 were 719,619 SEK, a sharp decline from 2,015,201 SEK in 2023, with a net loss of -10,162,729 SEK compared to -8,043,568 SEK last year.

• Cash and cash equivalents at year-end were 5,593,433 SEK, down from 9,599,946 SEK.

• Major scientific recognition and increased owner commitment, with the largest shareholder raising their stake above 15%.

• PEXA's technology continues to gain validation in international research and clinical studies, with new market opportunities emerging.

Financial highlights

• Q4 2024 net sales were 468,418 SEK, down from 544,461 SEK in Q4 2023.

• Full-year net loss after financial items was -10,162,729 SEK, compared to -8,043,568 SEK in 2023.

• Earnings per share for 2024 were -0.18 SEK, slightly improved from -0.19 SEK in 2023.

• Cash flow from operations for 2024 was -9,847,857 SEK, compared to -7,678,946 SEK in 2023.

• Total assets at year-end were 10,186,505 SEK, down from 15,365,682 SEK.

Outlook and guidance

• Management sees strong potential in expanding diagnostic applications and global market reach, supported by ongoing and new clinical studies.

• Additional capital will be required to fund operations and planned growth over the next 12 months.

• Focus remains on leveraging research results to develop diagnostic products for broader clinical use.